Search by Drug Name or NDC
NDC 00069-0520-02 Ngenla 60 mg/1.2mL Details
Ngenla 60 mg/1.2mL
Ngenla is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is SOMATROGON.
MedlinePlus Drug Summary
Somatrogon-ghla injection is used to replace growth hormone (a natural hormone produced by your body) and to increase growth in children 3 years of age or older with growth hormone deficiency. Somatrogon-ghla is a human growth hormone (hGH) analog. It works by replacing growth hormones that are normally produced in the body.
Related Packages: 00069-0520-02Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Somatrogon-ghla injection
Product Information
| NDC | 00069-0520 |
|---|---|
| Product ID | 0069-0520_7d29ea18-6a49-4219-bc89-e3ebce870551 |
| Associated GPIs | |
| GCN Sequence Number | 083178 |
| GCN Sequence Number Description | somatrogon-ghla PEN INJCTR 60MG/1.2ML SUBCUT |
| HIC3 | P1A |
| HIC3 Description | GROWTH HORMONES |
| GCN | 52063 |
| HICL Sequence Number | 047896 |
| HICL Sequence Number Description | SOMATROGON-GHLA |
| Brand/Generic | Brand |
| Proprietary Name | Ngenla |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | somatrogon-ghla |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 60 |
| Active Ingredient Units | mg/1.2mL |
| Substance Name | SOMATROGON |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761184 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00069-0520-02 (00069052002)
| NDC Package Code | 0069-0520-02 |
|---|---|
| Billing NDC | 00069052002 |
| Package | 1 CARTRIDGE in 1 CARTON (0069-0520-02) / 1.2 mL in 1 CARTRIDGE (0069-0520-01) |
| Marketing Start Date | 2023-08-14 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |